Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

Alzheimer's disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid-β, leading to the formation of …

Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

Microglia are resident cells of the brain that regulate brain development, maintenance of
neuronal networks, and injury repair. Microglia serve as brain macrophages but are distinct …

In vivo imaging, which enables us to peer deeply within living subjects, is producing
tremendous opportunities both for clinical diagnostics and as a research tool. Contrast …

Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein
aggregates that cause cellular toxicity and contribute to cellular proteostatic collapse …